ClinicalTrials.gg
CompletedNCT00599404Updated Apr 30, 2008

PK Study to Evaluate Esomeprazole Plasma Levels Following Administration of PN 400

A Phase 1 interventional study of PN400 in Healthy, sponsored by POZEN. Completed. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2008-04-30.

Sponsored by POZEN (part of Aralez Pharmaceuticals) · Phase 1, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Study summary

Pharmacokinetic study in healthy subjects with single and repeat b.i.d. dosing of PN 400 tablets from the same drug product batch.

02

Conditions studied

  • Healthy

Keywords

  • Pharmacokinetics study
03

In context

Lead sponsor

POZEN is the lead sponsor of 27 studies on the registry; none are open to participants now.

First submitted before POZEN became part of Aralez Pharmaceuticals.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Healthy male or non-pregnant female subjects between 18-55 years of age as well as other standard inclusion criteria for a study of this nature

Exclusion criteria

Exclusion Criteria:

Standard inclusion criteria for a study of this nature

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic profile following dosing with PN400

    Time frame: 24-hour PK on Day 1 & Day 10 of each treatment period

Secondary outcomes

  1. To evaluate the safety of PN400

    Time frame: Day 1-10 of each treatment period

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2008, a primary completion of Feb 2008 and a completion of Feb 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 11, 2008
First posted
Jan 23, 2008
Start
Jan 2008
Primary completionActual
Feb 2008
CompletionActual
Feb 2008
Last update
Apr 30, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00599404
Lead sponsor
POZEN
First posted
Jan 23, 2008
Start date
Jan 2008
Primary completion
Feb 2008
Completion
Feb 2008
Last update
Apr 30, 2008

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Naproxen · Esomeprazole

Start the discussion